[Link]
http://crossmark.crossref.org/dialog/?doi=10.1016/j.bcp.2013.09.016&domain=pdf
[Link]
http://crossmark.crossref.org/dialog/?doi=10.1016/j.bcp.2013.09.016&domain=pdf
[Link]
http://dx.doi.org/10.1016/j.bcp.2013.09.016
[Link]
mailto:benke@pharma.uzh.ch
[Link]
http://www.sciencedirect.com/science/journal/00062952
[Link]
http://dx.doi.org/10.1016/j.bcp.2013.09.016
Commentary
GABA
B
receptor trafficking and interacting proteins: Targets for the
development of highly specific therapeutic strategies to treat
neurological disorders?
Dietmar Benkea,b,*
aInstitute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
bNeuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland
1. Introduction
Normal brain function depends on precisely balanced
excitatory and inhibitory neurotransmission. A reduced inhibitorytonehasbeenassociatedwithawidevarietyofneurological
disorders including anxiety, depression, epilepsy and neuropathic pain(for recent reviews see [1–4]). Inhibitionin the brain
is predominantly mediated by GABA through activation of two
distinct receptors. Ionotropic GABA
A
receptors constitute integral Cl channels and convey fast inhibition, whereas metabotropicGABA
B
receptorsactvia G-proteinsona slowertimescale.
By activating G
i/o
proteins, GABA
B
receptors control three
main downstream effectors: voltage-sensitive Ca2+ channels,
inwardly-rectifying K+ channels and adenylyl cyclases. GABA
B
receptors areabundantlyexpressedthroughoutthecentralnervous
system in virtually all types of neurons. They are predominantly
localizedatextrasynapticsitestocontroltheexcitabilityofneurons
by inhibiting transmitter release and/or hyperpolarizing the
neuronal membrane (for recent reviews see [5–7]).
Functional GABA
B
receptors are composed of the two
subunits GABA
B1
and GABA
B2
, which carry distinct functions.
GABA
B1
harbors the binding site for GABA in the large
extracellular located N-terminal domain [8], whereas GABA
B2
is required for high affinity agonist binding to GABA
B1
[9,10],
carries a binding site for allosteric modulators in the heptahelical domain [11] and recruits the G-protein [12–14]. GABA
B1
exists in two variants, GABA
B1a
and GABA
B1b
, generated by
alternative promoter usage [15], differing solely in their N-
terminal amino acid sequences. They give rise to two GABA
B
receptor subtypes (GABA
B1a2
and GABA
B1b2
), with GABA
B1a2
preferentially localized presynaptically and GABA
B1b2
mainly
found postsynaptically [16].
Biochemical Pharmacology 86 (2013) 1525–1530
A R T I C L E I N F O
Article history:
Received 19 August 2013
Accepted 20 September 2013
Available online 29 September 2013
Keywords:
GABAB receptor
Cerebral ischemia
Neuropathic pain
Trafficking
Interacting proteins
A B S T R A C T
GABA
B
receptors mediate slow inhibitory neurotransmission throughout the central nervous system
thereby controlling the excitability of neurons. They have been implicated in numerous neurological
disorders making them an attractive drug target. However, due to considerable side effects, the agonist
baclofenisso far theonly drug onthemarket targetingGABA
B
receptors, primarily forthetreatment of
spasticity. Because GABA
B
receptors are involved in a variety of brain functions it is rather unlikely to
avoidunwantedeffectswithsystemicallyadministereddrugsdirectlyaddressingligandbindingsitesof
thereceptor.Tominimizesideeffects, itwouldbedesirabletotarget only thosereceptors involved ina
given pathological state. This commentary discusses the idea that restoring impaired GABA
B
receptor
function in diseased neurons by interfering with receptor–protein interactions may be an approach to
specifically target only those receptors involved in the pathological state. Two recently discovered
mechanisms that down-regulate the level of functional GABA
B
receptors most likely contribute to
cerebral ischemia and neuropathic pain, respectively. In both mechanisms, small interfering peptides
disrupting protein–protein interactions may offer a highly specific means to restore normal receptor
functionselectivelyatthesiteofmalfunction.IfrestoredfunctionalGABA
B
receptorexpressioninthese
diseaseshasbeneficialeffects,thismayserveasastartingpointforthedevelopmentofahighlyspecific
therapeuticinterventions.Suchanapproachisexpectedtominimizesideeffectsbecauseitpromisesto
leave those GABA
B
receptors unaffected which are not involved in the dysfunction.
 2013 Elsevier Inc. All rights reserved.
* Correspondence to: Institute of Pharmacology and Toxicology, University of
Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Tel.: +41 44 635 5930;
fax: +41 44 635 6874.
E-mail address: benke@pharma.uzh.ch
Contents lists available at ScienceDirect
Biochemical Pharmacology
journal homepage: www.elsevier.com/locate/biochempharm
0006-2952/$ – see front matter 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bcp.2013.09.016
(8.0.0.2542.1623836600 PDF Extractor SDK TRIAL VERSIOn)
Because GABA
B
receptors are involved in a variety of brain
functions, they have been implicated in numerous neurological
disorders including addiction, anxiety, cerebral ischemia, depression
, epilepsy, neuropathic pain, and spasticity making them an
attractive drug target [7,17]. Although substantial efforts in drug
development has been made during the past decades the agonist
baclofen is so far the only drug on the market targeting GABA
B
receptors, primarily for the treatment of spasticity [17]. Considerable side effects unfortunately prevented the broad therapeutic
application of orthosteric GABA
B
receptor ligands so far.
The recent discovery of allosteric GABA
B
receptor ligands
revived the interest in GABA
B
receptors as drug target [18]. These
ligandsseemtobeassociatedwithareducedprofileofsideeffects
and are currently evaluated for the treatment of anxiety, nicotine
and alcohol addiction as well as osteoarthritis and neuropathic
pain[19].However,likeorthostericligands,theycarrytheinherent
problem to modulate the activity of an abundant receptor that is
involved in a variety of brain functions. It is therefore rather
unlikelytoavoidunwantedeffectswithsystemicallyadministered
drugs binding to orthosteric or allosteric binding sites. To avoid
this disadvantage, itwouldbedesirable to targetselectivelythose
receptorsinvolvedinagivenpathologicalstateandleavereceptors
inhealthyneuronsunaffected.Thereisevidencethatneurological
disorders are associated with the down-regulation of GABA
B
receptors,presumablycausedbyimpairedtraffickingmechanisms
and/or interaction with receptor associated proteins [20–24].
These protein dynamics affect the excitation-inhibition balance
and likelycontributeto thedisease state. Therefore, restorationof
the normal level of functional GABA
B
receptors in pathological
conditions may be a highly specific means to counteract at least
some aspects of the disease pathology.
This commentary explores the potential of two recently
discovered mechanisms that affect the level of functional GABA
B
receptors as starting points for the development of therapeutic
interventions for the treatment of cerebral ischemia and neuropathic pain. In the first mechanism, excessive activation of
glutamatereceptorsresultsindown-regulationofGABA
B
receptors
duetoimpairedrecyclingofthereceptorsandsortingtolysosomes
fordegradation.Inthesecondmechanism,up-regulationofaGABA
B
receptor interacting protein under conditions of neuropathic pain
suppresses GABA
B
receptor function by disruption of the receptor
heterodimersatthecellsurface.Cell-penetratingsyntheticpeptides,
which interfere with the protein–protein interactions causing
GABA
B
receptor down-regulation, are expected to restore normal
receptor function selectively at the site of malfunction. If restoring
normal receptor function alleviates the pathological state, this
approach offers the opportunity for the development of highly
specific therapeutic interventions.
2. GABA
B
receptors and cerebral ischemia
Stroke is a leading cause of mortality and acquired disability
with tremendous economic and social costs. Abrupt blockade of
blood supply deprives neurons from oxygen and energy, which
rapidly leads to metabolic derailment and neuronal death.
Restoration of blood circulationwith thrombolyticdrugs immediately after the insult is currently the only available therapeutic
treatment to limit irreparable loss of neurons. Unfortunately, all
efforts to pharmacologically prevent ischemic cell death in the
clinic remain unsuccessful so far [25,26]. Excessive activation of
glutamatereceptorsisthoughttobethemaintriggerforischemiainduced death of neurons [27,28]. Because GABA
B
receptors
control neuronal excitability and the activity of glutamate
receptors [6] it is not surprising that persistent activation of
GABA
B
receptors with baclofen during and immediately after the
ischemic insult effectively diminishes neuronal death in different
experimental animal models of cerebral ischemia [29–37]. There
arehintsthatGABA
B
receptorexpressionisreducedaftertransient
cerebral ischemia [30,38,39], suggesting that impaired GABA
B
receptor-mediated inhibition may contribute to excitotoxic cell
death. Restoring or preserving normal GABA
B
receptor expression
levels may therefore be a promising approach to counteract
ischemic cell damage by keeping excessive glutamatergic neurotransmission under the inhibitory control of GABA
B
receptors.
There are observations in favor of this hypothesis. Intravenous
applicationofferulicacid,acomponentofherbsusedintraditional
Chinese medicine (Anglica sinensis, Ligusticum chuoanxiong), has
been shown to enhance GABA
B1
expression in the ischemic tissue
and to reduce ischemic cell damage [40]. In addition, mild
hypothermia exerts a robust neuroprotective effect and has been
shown to be associated with increased GABA
B1
expression in the
ischemicbrain[39].However,acausallinkbetweenup-regulation
of GABA
B
receptor subunits and neuroprotection is lacking so far.
Recent studies simulating in cultured neurons the excessive
activation of glutamate receptors that occur during cerebral
ischemia revealed a mechanism that rapidly down-regulates
GABA
B
receptors. Assuming that the loss of GABA
B
receptormediated control of excitatory neurotransmission under ischemic
conditions contributes to excitotoxicity, attempts to restore
normal levels of functional GABA
B
receptors may serve as a
starting point for thedevelopment of a highly specific therapeutic
intervention to counteract neuronal death. Application of glutamate to cultures of cortical or hippocampal neurons led within
minutes to a rapid removal of GABA
B
receptors from the cell
surface and was consequently accompanied by a loss of GABA
B
receptor-mediated inhibition [41–43]. Down-regulation of GABA
B
receptors required activation of NMDA receptors and Ca2+ influx
throughL-type voltage-gatedCa2+channels, conditionsthat occur
during cerebral ischemia. Mechanistically, the loss of cell surface
receptors was due to re-routing the receptors from the recycling
pathway to lysosomes for degradation (Fig. 1) [41,43]. Under
normal conditions, cell surface GABA
B
receptors constitutively
internalize via the clathrin and dynamin-dependent pathway and
PP2A
CaMKII
P 
P 
Sustained glutamate 
GB1 
Recycling
Normal
Lysosomal
degradation
Ca2+
GB2 
P 
AMPK
Fig. 1. Down-regulation of cell surface GABA
B
receptors upon sustained activation
of glutamate receptors. Under normal conditions, GABA
B
receptors are
constitutively endocytozed via the classical clathrin and dynamin-dependent
pathway.Themajorityofinternalizedreceptorsaresortedtotherecyclingpathway
for reinsertion into the plasma membrane, while a minor fraction is degraded in
lysosomes. Sustained activation of AMPA and NMDA receptors, conditions that
occur in cerebral ischemia, leads to elevated intracellular Ca2+ levels. This induces
phosphorylation of GABA
B1
by CaMKII and GABA
B2
by AMP kinase, which is
followed by PP2A-mediated dephosphorylation. These phosphorylation/
dephosphorylation events result in sorting the receptors preferentially to
lysosomes for degradation. Because the kinetic of constitutive endocytosis
remains unaffected, the impaired recycling of the receptors leads to downregulation of the receptors. AMPK, AMP kinase; CaMKII, Ca2+/calmodulindependent protein kinase II; GB1, GABA
B
receptor subunit GABA
B1
; GB2, GABA
B
receptor subunit GABA
B1
; PP2A, protein phosphatase 2A.
D. Benke/Biochemical Pharmacology 86 (2013) 1525–1530 1526
(BY PDF Extractor SDK TRIAL VERSION)
the majority of endocytosed receptors recycle to the cell surface
[44–48]. Sustained activation of glutamate receptors did not
influence the kinetics of receptor endocytosis [41] but inhibited
recycling of the receptors resulting in increased sorting to
lysosomes for destruction [41,43]. The underlying mechanism
appears to be based on a sequence of phosphorylation and
dephosphorylation steps (Fig. 1). The glutamate receptormediated rise of intracellular Ca2+ and a lower ATP/AMP ratio
activates two protein kinases: Ca2+/calmodulin-dependent protein kinase II (CaMKII) and AMP kinase. CaMKII binds to GABA
B
receptorsandphosphorylatesGABA
B1
onSer867[42].Mutational
inactivationofthisCaMKIIphosphorylationsiteabolisheddownregulation of GABA
B
receptors, indicating that CaMKII-dependent phosphorylation of GABA
B1
is a key step in this process. In
addition, AMP kinase initially phosphorylates serine 783 in
GABA
B2
,whichisthenfollowedbydephosphorylationbyprotein
phosphatase 2A (PP2A) [43]. Phosphorylation of serine 783 in
GABA
B2
by AMP kinase has been shown to stabilize functional
GABA
B
receptors [49]. In this sense, phosphorylation of serine
783 in GABA
B2
appears to be a reaction to counteract downregulation of GABA
B
receptor. However, its subsequent dephosphorylation overrides this effect. Interestingly, mutational
inactivation of this phosphorylation site led to a reduction of
cell surface receptors and to an intracellular localization of
GABA
B
receptors resembling the situation observed after
sustained glutamate receptor activation [43]. This suggests that
phosphorylationofserine783inGABA
B2
isasignalforsortingthe
receptors to the recycling pathway and dephosphorylation by
PP2A routes the receptors to lysosomes for degradation. The
preciseroleofglutamate-inducedCaMKII-dependentphosphorylationofserine867inGABA
B1
issofarunresolved.Itmayserve
asasignaldownstreamofPP2AactionsortingGABA
B
receptorsto
the degradation pathway or it may be required for recruiting
PP2A to the receptors.
Both, glutamate-induced CaMKII and PP2A interaction with
GABA
B
receptors offer a potential approach to inhibit downregulation of GABA
B
receptors to keep receptor levels normal
under ischemic conditions to counteract overexcitation and
excitotoxicity. Identification of the interaction sites for CaMKII
andPP2AwithGABA
B
receptorswouldpermitthedevelopment
ofsmallinterferingsyntheticpeptidestodisrupttheinteraction
and to prevent phosphorylation of serine 867 in GABA
B1
or
dephosphorylation of serine 783 in GABA
B2
, respectively.
Preventing dephosphorylation of serine 783 in GABA
B2
has the
addedbenefitthatitsupportsphosphorylationofthisresidueby
AMP kinase, which has been shown to occur under ischemic
conditions and to convey neuroprotection by stabilizing GABA
B
receptor function [49]. Because phosphorylation of GABA
B1
serine 867 and dephosphorylation of GABA
B2
serine 783
specifically take place in the ischemic area this approach is
expected to affect only those GABA
B
receptors involved in the
insult.
3. GABA
B
receptors and neuropathic pain
Injury of the nervous system or diseases such as cancer,
diabetes or multiple sclerosis can lead to neuropathic pain. This
form of chronic pain affects a considerable fraction of the
population and is only unsatisfactorily addressed pharmacologically [50,51]. Neuropathic pain is associated with diminished
inhibitory control of dorsal horn neurons in the spinal cord [4].
ActivationofGABA
B
receptors,whichareabundantlyexpressedin
primaryafferentterminalsandneuronsinthesuperficiallayersof
the dorsal horn [52–55], provides analgesia in experimental
animals as well as in humans [56]. Accordingly, mutant mice
lacking GABA
B
receptors exhibit hyperalgesia [57,58]. This
suggests that down-regulation of GABA
B
receptors might contribute to the diminished inhibitory control of spinal cord neurons.
There are indeed recent studies indicating reduced expression of
GABA
B
receptors in dorsal root ganglia [59] and in the spinal cord
dorsal horn [24,60] in animal models of neuropathic pain. This
correlates well with an increased glutamatergic input from
primary afferents on lamina II neurons due to reduced GABA
B
receptor function on primary afferent terminals in a rat model of
diabetic neuropathic pain [61].
A recent study proposed an intriguing and unexpected
mechanism as to how GABA
B
receptor activity is down-regulated
under conditions of neuropathic pain (Fig. 2). After inducing
neuropathic pain in rats by spinal nerve ligation, the GABA
B
receptor interacting protein 14-3-3z was selectively up-regulated
intheipsilateralsuperficiallayersofthedorsalhorninthelumbar
spinal cord [20]. In this area nociceptive signal processing in
response to the injury takes place. 14–3-3 proteins regulate
numerous cellular processes by interacting with a variety of
distinct proteins and alterations in the expression level of 14–3-3
proteins has been observed in several diseases [62]. It has been
Fig. 2. Upregulation of 14-3-3z under conditions of neuropathic pain disrupts GABA
B
receptor heterodimers in the plasma membrane. GABA
B
receptors are heterodimers
composedofGABA
B1
andGABA
B2
.BindingofGABAtoGABA
B1
activatesGi/oproteinsrecruitedbyGABA
B2
forsignaltransduction.Afterinductionofneuropathicpainbyspinal
nerve ligation, 14-3-3z is upregulated in the affected spinal cord neurons, interacts with GABA
B1
and thereby disrupts the receptor heterodimer. This results in a loss of
functional GABAB receptors.
D. Benke/Biochemical Pharmacology 86 (2013) 1525–1530 1527
( 8.0.0.2542.84847675 PDF Extractor SDK EVALUATION)
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0005
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0005
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0010
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0010
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0015
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0015
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0020
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0020
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0020
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0025
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0025
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0025
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0030
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0030
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0030
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0035
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0035
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0035
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0040
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0040
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0040
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0040
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0040
shown already a while ago that 14-3-3z interacts with GABA
B1
[63].14-3-3zbindstoasitethatpartiallyoverlapswiththecoiledcoilmotifintheC-terminaldomainofGABA
B1
,whichisthoughtto
be involved in heterodimerization of the receptor complex. Thus,
binding of 14-3-3z to GABA
B1
might exclude the association of
GABA
B1
and GABA
B2
. Indeed, up-regulation of 14-3-3z by spinal
nerve ligation led to the interaction of 14-3-3z with GABA
B1
exclusively in the plasma membrane of neurons in the affected
dorsal horn and disrupted the GABA
B1
/GABA
B2
heterodimers [20].
This resulted in non-functional receptors and diminished GABA
B
receptor signaling. Themechanismas to how a moderate increase
of 14-3-3z levels is able to disrupt already existing receptor
heterodimers, which are expected in a thermodynamically stable
state, remains unclear. Because 14-3-3 proteins predominantly
bind to phosphoserine and phosphothreonine containing motifs,
spinal nerve ligation may induce phosphorylation of GABA
B1
within the 14-3-3z interaction site initiating the binding 14-3-3z
to GABA
B1
and consequently disruption of the GABA
B1
/GABA
B2
heterodimer.
Interfering with the GABA
B1
/14-3-3z interaction by siRNA-
mediatedknock-downof14-3-3proteinsorwithasmallsynthetic
peptidemimickingtheGABA
B1
bindingsiterestoredexpressionof
functionalGABA
B
receptorheterodimersintheplasmamembrane
and consequently enhanced the analgesic activity of intrathecally
injected baclofen [20]. Intriguingly, even injection of the interferingsyntheticpeptideintheneuropathicratspartiallyreversedthe
pain. This suggests that down-regulation of GABA
B
receptor
signaling is one factor involved in the expression of neuropathic
painand,mostimportantly,thatnormalcellsurfacereceptorlevels
can be restored under conditions of fully expressed neuropathic
pain states.Because14-3-3z expressionisselectively enhancedat
thesiteofnociceptiveprocessingintheaffecteddorsalhornofthe
spinal cord,preventing itsinteractionwithGABA
B
receptors using
interfering peptides provides the opportunity to develop a highly
selective therapeutic strategy to reduce neuropathic pain without
affecting GABA
B
receptors not involved in the diseases.
4. Conclusion
To reduce side effects that are inherently associated with
systemically administered drugs targeting orthosteric and allosteric receptor binding sites of GABA
B
receptors it would be
desirable to pharmacologically address only those receptors
involved in particular disease states. Interfering with protein–
protein interactions that specifically occur in the diseased tissue
and affect receptor signaling offers the opportunity to develop
highly selective therapeutic interventions. Both mechanisms
discussed here reduce the levels of functional GABA
B
receptors
under conditions of cerebral ischemia and neuropathic pain
resultingindiminishedinhibitorycontrolofneuronalexcitation.
Restoring normal levels of functional receptors with small
interfering peptides targeting the GABA
B2
-PP2A interaction in
cerebral ischemia or the GABA
B1
-14-3-3z interaction in neuropathic pain offer starting points for exploring its potential of
highly selective treatments. In case of neuropathic pain the
available data is promising because the beneficial effect of
interfering with the GABA
B1
-14-3-3z interaction is already
documented using an animal model. However, in case of downregulation of GABA
B
receptors under ischemic conditions
substantial research is required to verify the hypothesis that
restoring normal levels of functional GABA
B
receptors limits
excitotoxicity.Disruptingreceptorinteractionswhichspecifically
occurindiseasedneuronstargetsonlythosereceptorsinvolvedin
the pathological state and would spare the receptors in healthy
neurons ensuring their normal physiological signaling. This is
expected to minimize side effects.
One issue of preventing protein–protein interactions in vivo is
the delivery of the interfering peptides to the site of action. The
main hurdles are low oral bioavailability, high biodegradability
andlowcellularuptake[64].Afteroralapplicationthepeptidesare
exposed to large amounts of proteases and peptidases in the
gastro-intestinal tract which can quickly degrade the peptide. In
addition, peptides are poorly taken up by the intestinal mucosa
which limits their access to the circulatory system. Therefore,
intravenous injection remains the best administration route of
therapeuticpeptides.Toincreasethehalf-lifeofthepeptidesinthe
plasma, they are usually optimized to increase their stability and
resistancetoproteolyticcleavage.Thisincludesalanineoraspartic
acid scanningto eliminatepotentialcleavage sites, substitution of
natural L-amino acids by D-amino acids, chemical modification of
N- and C-termini and isosteric replacementof peptidebonds [64].
A further complication associated with targeting central
neurons is that the peptides have to cross the blood brain barrier.
Cell-penetrating peptides, such as TAT(47-67) derived from the
human immunodeficiency virus (HIV-1) trans-acting activator of
transcription (TAT) protein, fused to the interfering peptide of
interest have been shown to overcome this problem [65,66].
However,thesepeptidecarrierslackcell-specificity.Itwouldbeof
greatadvantagetodelivertheinterferingpeptidesselectivelyinto
neurons to spare cells and tissues not involved in the disease.
Recently, peptides derived from rabies virus glycoprotein have
beenshowntotargetcargosspecificallyintoneurons[67,68]viaan
endocytoticmechanismafterintravenousinjection[69].Thisnovel
development indicates that a neuron-selective delivery of therapeutic peptides may be achievable.
The feasibility of employing synthetic peptides to disrupt
protein–protein interactions as therapeutic approach has been
demonstratedinthecaseofinterferencewiththeNMDAreceptor-
PSD95 interaction to reduce neuronal cell death in cerebral
ischemia [70,71]. The scaffolding protein PSD95 couples NMDA
receptors to neuronal nitric oxide synthase which is essential for
NMDA receptor-dependent excitotoxicity. Disruption of the
complex with a cell-penetrating synthetic peptide (Tat-NR2B9c)
afterinductionofcerebralischemiainratsandnon-humanprimates
significantlyreducedinfarctvolumeaswellasneurologicaldeficits
[70,71]. A phase II clinical trial evaluating the safety and effectiveness of Tat-NR2B9c in patients with stroke after endovascular
aneurysmrepairshowedlowerstrokeincidenceinpatientstreated
with the peptide compared to the placebo group [72].
Acknowledgement
The work of the author is supported by grants of the Swiss
National Science Foundation.
References
[1] Mohler H. The GABA system in anxiety and depression and its therapeutic
potential. Neuropharmacology 2012;62:42–53.
[2] GrabenstatterHL,RussekSJ,Brooks-KayalAR.Molecularpathwayscontrolling
inhibitory receptor expression. Epilepsia 2012;53(Suppl. 9):71–8.
[3] Yin DM, Chen YJ, Sathyamurthy A, Xiong WC, Mei L. Synaptic dysfunction in
schizophrenia. Adv Exp Med Biol 2012;970:493–516.
[4] Zeilhofer HU, Benke D, Yevenes GE. Chronic pain states: pharmacological
strategies to restore diminished inhibitory spinal pain control. Annu Rev
Pharmacol Toxicol 2012;52:111–33.
[5] Gassmann M, Bettler B. Regulation of neuronal GABA
B
receptor functions by
subunit composition. Nat Rev Neurosci 2012;13:380–94.
[6] ChalifouxJR,CarterAG.GABA
B
receptormodulationofsynapticfunction.Curr
Opin Neurobiol 2011;21:1–6.
[7] BenarrochEE.GABABreceptors:structure,functions,andclinicalimplications.
Neurology 2012;78:578–84.
[8] Galvez T, Parmentier ML, Joly C, Malitschek B, Kaupmann K, Kuhn R, et al.
Mutagenesis and modeling of the GABA
B
receptor extracellular domain support a Venus flytrap mechanism for ligand binding. J Biol Chem
1999;274:13362–69.
D. Benke/Biochemical Pharmacology 86 (2013) 1525–1530 1528
(EVAL PDF Extractor SDK 8.0.0.2542-1567109136)
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0045
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0045
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0045
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0050
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0050
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0050
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0050
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0055
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0055
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0055
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0055
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0055
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0060
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0060
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0060
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0060
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0065
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0065
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0065
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0065
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0065
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0070
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0070
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0070
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0070
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0070
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0075
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0080
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0080
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0080
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0080
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0085
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0085
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0085
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0090
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0095
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0095
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0095
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0100
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0105
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0105
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0105
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0105
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0110
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0110
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0110
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0110
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0115
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0115
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0115
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0115
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0115
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0120
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0120
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0120
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0120
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0125
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0125
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0130
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0130
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0130
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0135
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0140
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0140
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0145
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0145
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0145
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0145
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0150
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0150
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0150
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0150
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0155
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0155
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0155
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0155
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0160
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0160
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0160
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0160
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0165
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0165
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0165
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0165
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0170
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0170
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0170
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0170
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0170
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0175
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0175
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0180
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0180
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0180
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0180
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0185
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0185
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0185
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0185
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0190
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0190
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0190
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0190
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0195
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0200
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0200
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0200
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0200
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0200
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0205
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0205
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0205
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0205
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0210
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0210
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0210
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0210
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0210
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0215
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0215
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0215
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0215
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0215
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0220
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0220
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0220
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0220
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0225
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0230
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0235
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0235
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0235
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0235
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0240
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0240
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0240
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0240
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0240
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0245
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0245
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0245
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0245
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0250
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0250
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0250
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0255
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0255
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0255
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0260
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0260
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0260
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0265
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0265
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0265
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0270
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0270
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0270
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0270
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0275
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0275
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0275
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0275
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0280
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0280
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0280
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0285
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0290
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0290
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0290
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0290
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0295
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0300
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0300
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0300
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0300
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0305
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0305
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0305
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0310
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0310
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0315
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0315
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0315
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0315
[9] Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, et al. Allosteric
interactions between GB1 and GB2 subunits are required for optimal GABAB
receptor function. EMBO J 2001;20:2152–9.
[10] Liu J, Maurel D, Etzol S, Brabet I, Ansanay H, Pin JP, et al. Molecular determinants involved in the allosteric control of agonist affinity in the GABA
B
receptor by the GABA
B2
subunit. J Biol Chem 2004;279:15824–30.
[11] BinetV,BrajonC,LeCorreL,AcherF,PinJP,PrezeauL.Theheptahelicaldomain
ofGABA
B2
is activated directlybyCGP7930, a positiveallosteric modulator of
the GABA
B
receptor. J Biol Chem 2004;279:29085–91.
[12] Duthey B, Caudron S, Perroy J, Bettler B, Fagni L, Pin JP, et al. A single subunit
(GB2) is required for G-protein activation bythe heterodimeric GABA
B
receptor. J Biol Chem 2002;277:3236–41.
[13] HavlickovaM,PrezeauL,DutheyB,BettlerB,PinJP,BlahosJ.Theintracellular
loopsoftheGB2subunitarecrucialforG-proteincouplingoftheheteromeric
g-aminobutyrate
B
receptor. Mol Pharmacol 2002;62:343–50.
[14] Robbins MJ, Calver AR, Filippov AK, Hirst WD, Russell RB, Wood MD, et al.
GABA
B2
isessentialforG-proteincouplingoftheGABA
B
receptorheterodimer.
J Neurosci 2001;21:8043–52.
[15] Steiger JL, Bandyopadhyay S, Farb DH, Russek SJ. cAMP response elementbinding protein, activating transcription factor-4, and upstream stimulatory
factor differentially control hippocampal GABA
BR1a
and GABA
BR1b
subunit
gene expression through alternative promoters. J Neurosci 2004;24:
6115–26.
[16] VigotR,BarbieriS,Bra ¨uner-OsborneH,TurecekR,ShigemotoR,ZhangYP,etal.
Differential compartmentalization and distinct functions of GABA
B
receptor
variants. Neuron 2006;50:589–601.
[17] BoweryNG.GABA
B
receptor:asiteoftherapeuticbenefit.CurrOpinPharmacol
2006;6:37–43.
[18] Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, et al.
Positive allosteric modulation of native and recombinant g-aminobutyric
acidBreceptorsby2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol
2001;60:963–71.
[19] FroestlW.NovelGABA
B
receptorpositivemodulators:apatentsurvey.Expert
Opin Ther Pat 2010;20:1007–17.
[20] Laffray S, Bouali-Benazzouz R, Papon MA, Favereaux A, Jiang Y, Holm T, et al.
Impairment of GABA
B
receptor dimer by endogenous 14-3-3z in chronic pain
conditions. EMBO J 2012;31:3239–51.
[21] StraessleA,LoupF,ArabadziszD,OhningGV,FritschyJM.Rapidandlong-term
alterations of hippocampal GABA
B
receptors in a mouse model of temporal
lobe epilepsy. Eur J Neurosci 2003;18:2213–26.
[22] Merlo D, Mollinari C, Inaba Y, Cardinale A, Rinaldi AM, D‘Antuono M, et al.
ReducedGABABreceptorsubunitexpressionandpaired-pulsedepressionina
genetic model of absence seizures. Neurobiol Dis 2007;25:631–41.
[23] MizukamiK,IshikawaM,HidakaS,IwakiriM,SasakiM,IritaniS.ImmunohistochemicallocalizationofGABA
B
receptorintheentorhinalcortexandinferior
temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol
Psychiatry 2002;26:393–6.
[24] WangXL,ZhangQ,ZhangYZ,LiuYT,DongR,WangQJ,etal.Downregulationof
GABAB receptors in the spinal cord dorsal horn in diabetic neuropathy.
Neurosci Lett 2011;490:112–5.
[25] Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future.
Neuropharmacol 2008;55:363–89.
[26] O‘CollinsVE,MacleodMR,Donnan GA,HorkyLL,vanderWorpBH,Howells
DW. 1026 Experimental treatments in acute stroke. Ann Neurol
2006;59:467–77.
[27] LiptonP.Ischemiccelldeathinbrainneurons.PhysiolRev1999;79:1431–568.
[28] Kostandy BB. The role of glutamate in neuronal ischemic injury: the role of
spark in fire. Neurol Sci 2012;33:223–37.
[29] BabcockAM,EveringhamA,PadenCM,KimuraM.Baclofenisneuroprotective
and prevents loss of calcium/calmodulin-dependent protein kinase II immunoreactivity in the ischemic gerbil hippocampus. J Neurosci Res 2002;67:
804–11.
[30] Cimarosti H, Kantamneni S, Henley JM. Ischaemia differentially regulates
GABAB receptor subunits in organotypic hippocampal slice cultures. Neuropharmacol 2009;56:1088–96.
[31] Dave KR, Lange-Asschenfeldt C, Raval AP, Prado R, Busto R, Saul I, et al.
Ischemic preconditioning ameliorates excitotoxicity by shifting glutamate/
g-aminobutyric acid release and biosynthesis. J Neurosci Res 2005;82:
665–73.
[32] Han D, Zhang QG, Yong L, Li C, Zong YY, Yu CZ, et al. Co-activation of GABA
receptors inhibits the JNK3 apoptotic pathway via the disassembly of the
GluR6-PSD95-MLK3 signaling module in cerebral ischemic-reperfusion. FEBS
Lett 2008;582:1298–306.
[33] Jackson-FriedmanC,LydenPD,NunezS,JinA,ZweiflerR.Highdosebaclofenis
neuroprotectivebutalsocausesintracerebralhemorrhage:aquantalbioassay
study using the intraluminal suture occlusion method. Exp Neurol
1997;147:346–52.
[34] Kulinskii VI, Mikhel’son GV. Additivity and independence of neuroprotective
effects of GABA
A
and GABA
B
receptor agonists in complete global cerebral
ischemia. Bull Exp Biol Med 2000;130:772–4.
[35] LalS,ShuaibA,IjazS.Baclofeniscytoprotectivetocerebralischemiaingerbils.
Neurochem Res 1995;20:115–9.
[36] Xu J, Li C, Yin XH, Zhang GY. Additive neuroprotection of GABAA and GABAB
receptoragonistsincerebralischemicinjuryviaPI-3K/Aktpathwayinhibiting
the ASK1-JNK cascade. Neuropharmacol 2008;54:1029–40.
[37] Zhang F, Li C, Wang R, Han D, Zhang QG, Zhou C, et al. Activation of GABA
receptors attenuates neuronal apoptosis through inhibiting the tyrosine
phosphorylation of NR2A by Src after cerebral ischemia and reperfusion.
Neuroscience 2007;150:938–49.
[38] Vollenweider F, Bendfeldt K, Maetzler W, Otten U, Nitsch C. GABA
B
receptor
expression and cellular localization in gerbil hippocampus after transient
global ischemia. Neurosci Lett 2006;395:118–23.
[39] KimJY,KimN,YenariMA,ChangW.MildHypothermiasuppressescalciumsensing receptor (CaSR) induction following forebrain ischemia while increasing GABA
B
receptor 1 (GABA
B
R1) Expression. Transl Stroke Res
2011;2:195–201.
[40] ChengCY,SuSY,TangNY,HoTY,LoWY,HsiehCL.Ferulicacidinhibitsnitric
oxide-induced apoptosis by enhancing GABA
B1
receptor expression in
transient focal cerebral ischemia in rats. Acta Pharmacol Sin 2010;31:
889–99.
[41] MaierPJ,MarinI,GramppT,SommerA,BenkeD.Sustainedglutamatereceptor
activation down-regulates GABA
B
receptors by shifting the balance from
recycling to lysosomal degradation. J Biol Chem 2010;285:35606–14.
[42] GuetgN,AzizSA,HolbroN,TurecekR,RoseT,SeddikR,etal.NMDAreceptordependent GABA
B
receptor internalization via CaMKII phosphorylation of
serine 867 in GABA
B1
. Proc Natl Acad Sci U S A 2010;107:13924–29.
[43] Terunuma M, Vargas KJ, Wilkins ME, Ramirez OA, Jaureguiberry-Bravo M,
Pangalos MN, et al. Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors. Proc
Natl Acad Sci U S A 2010;107:13918–23.
[44] GramppT,NotzV,BrollI,FischerN,ConstitutiveBenkeD.agonist-accelerated,
recycling and lysosomal degradation of GABA
B
receptors in cortical neurons.
Mol Cell Neurosci 2008;39:628–37.
[45] Grampp T, Sauter K, Markovic B, Benke D. g-Aminobutyric acid type B
receptors are constitutively internalized via the clathrin-dependent pathway
and targeted to lysosomes for degradation. J Biol Chem 2007;282:
24157–65.
[46] Vargas KJ, Terunuma M, Tello JA, Pangalos MN, Moss SJ, Couve A. The
availability of surface GABA
B
receptors is independent of g-aminobutyric
acid but controlled by glutamate in central neurons. J Biol Chem
2008;283:24641–48.
[47] Hannan S, Wilkins ME, Dehghani-Tafti E, Thomas P, Baddeley SM, Smart TG.
GABAB receptor internalisation is regulated by the R2 subunit. J Biol Chem
2011;286:24324–35.
[48] WilkinsME,LiX,SmartTG.TrackingcellsurfaceGABA
B
receptorsusinganabungarotoxin tag. J Biol Chem 2008;283:34745–52.
[49] Kuramoto N, Wilkins ME, Fairfax BP, Revilla-Sanchez R, Terunuma M, Tamaki
K,etal.Phospho-dependentfunctionalmodulationofGABABreceptorsbythe
metabolic sensor AMP-dependent protein kinase. Neuron 2007;53:233–47.
[50] Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of
chronic pain with neuropathic characteristics in the general population. Pain
2008;136:380–7.
[51] Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, et al.
Neuropathicpaininthecommunity:moreunder-treatedthanrefractory.Pain
2013;154:690–9.
[52] Price GW, Wilkin GP, Turnbull MJ, Bowery NG. Are baclofen-sensitive GABA
B
receptors present on primary afferent terminals of the spinal cord. Nature
1984;307:71–4.
[53] TowersS,PrincivalleA,BillintonA,EdmundsM,BettlerB,UrbanL,etal.GABA
B
receptor protein and mRNA distribution in rat spinal cord and dorsal root
ganglia. Eur J Neurosci 2000;12:3201–10.
[54] Yang K, Ma WL, Feng YP, Dong YX, Li YQ. Origins of GABA
B
receptor-like
immunoreactive terminals in the rat spinal dorsal horn. Brain Res Bull
2002;58:499–507.
[55] Ataka T, Kumamoto E, Shimoji K, Yoshimura M. Baclofen inhibits more
effectivelyC-afferentthanAd-afferentglutamatergictransmissioninsubstantia gelatinosa neurons of adult rat spinal cord slices. Pain 2000;86:
273–82.
[56] Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and
physiological functions of GABAB receptors. Physiol Rev 2004;84:835–67.
[57] Gassmann M, Shaban H, Vigot R, Sansig G, Haller C, Barbieri S, et al. Redistribution of GABAB1 protein and atypical GABAB responses in GABAB2-deficient
mice. J Neurosci 2004;24:6086–97.
[58] Schuler V, Luscher C, Blanchet C, Klix N, Sansig G, Klebs K, et al. Epilepsy,
hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA
B
responses in mice lacking GABA
B1
. Neuron 2001;31:47–58.
[59] Engle MP, Merrill MA, Marquez De Prado B, Hammond DL. Spinal nerve
ligation decreases g-aminobutyric acid
B
receptors on specific populations
of immunohistochemically identified neurons in L5 dorsal root ganglion of
the rat. J Comp Neurol 2012;520:1663–77.
[60] WuJ,XuY,PuS,JiangW,DuD.p38/MAPKinhibitormodulatestheexpression
of dorsal horn GABAB receptors in the spinal nerve ligation model of neuropathic pain. Neuroimmunomodulat 2011;18:150–5.
[61] Wang XL, Zhang HM, Chen SR, Pan HL. Altered synaptic input and GABAB
receptorfunctioninspinalsuperficialdorsalhornneuronsinratswithdiabetic
neuropathy. J Physiol 2007;579:849–61.
[62] Zhao J, Meyerkord CL, Du Y, Khuri FR, Fu H. 14-3-3 Proteins as potential
therapeutic targets. Semin Cell Dev Biol 2011;22:705–12.
[63] Couve A, Kittler JT, Uren JM,Calver AR, Pangalos MN,Walsh FS, etal. Association of GABA
B
receptors and members of the 14-3-3 family of signaling
proteins. Mol Cell Neurosci 2001;17:317–28.
D. Benke/Biochemical Pharmacology 86 (2013) 1525–1530 1529
(PDF Extractor SDK TRIAL VERSION)
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0320
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0320
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0325
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0325
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0330
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0330
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0335
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0335
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0335
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0340
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0340
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0340
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0345
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0345
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0345
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0350
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0350
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0350
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0355
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0355
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0360
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0360
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0360
[Link]
http://refhub.elsevier.com/S0006-2952(13)00621-7/sbref0360
[64] Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic
peptides: science and market. Drug Discov Today 2010;15:40–56.
[65] Milletti F. Cell-penetrating peptides: classes, origin, and current landscape.
Drug Discov Today 2012;17:850–60.
[66] Blumling Iii JP, Silva GA. Targeting the brain: advances in drug delivery. Curr
Pharma Biotech 2012;13:2417–26.
[67] Fu A, Wang Y, Zhan L, Zhou R. Targeted delivery of proteins into the central
nervoussystemmediatedbyrabiesvirusglycoprotein-derivedpeptide.Pharmaceut Res 2012;29:1562–9.
[68] Xiang L, Zhou R, Fu A, Xu X, Huang Y, Hu C. Targeted delivery of large fusion
protein into hippocampal neurons by systemic administration. J Drug Target
2011;19:632–6.
[69] Fu A, Zhao Z, Gao F, Zhang M. Cellular uptake mechanism and therapeutic
utility of a novel peptide in targeted-delivery of proteins into neuronal cells.
Pharmaceut Res 2013;30:2108–17.
[70] Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of
ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002;298:846–50.
[71] CookDJ,TevesL,TymianskiM.TreatmentofstrokewithaPSD-95inhibitorin
the gyrencephalic primate brain. Nature 2012;483:213–7.
[72] Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. Safety
and efficacy of NA-1 in patients with iatrogenic stroke after endovascular
aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebocontrolled trial. Lancet Neurol 2012;11:942–50.
D. Benke/Biochemical Pharmacology 86 (2013) 1525–1530 1530
(DEMO VERSION PDF Extractor SDK 8.0.0.2542.1463870325)
